SCHEMBL12640305

SCHEMBL12640305

CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCN(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
HPGD P15428 2/20 0.61
FAAH O00519 1/20 0.61
MAPT P10636 1/20 0.61
CNR1 P21554 1/20 0.61
CNR2 P34972 1/20 0.61
S1PR1 P21453 1/20 0.56
PRKCA P17252 2/20 0.54
PRKCE Q02156 1/20 0.54
PRKCQ Q04759 1/20 0.54
PRKCD Q05655 1/20 0.54
SLC6A5 Q9Y345 1/20 0.50
LPAR1 Q92633 1/20 0.49
F7 P08709 2/20 0.49
F3 P13726 2/20 0.49
DUSP3 P51452 1/20 0.49
PTPN7 P35236 1/20 0.49
KDM4E B2RXH2 1/20 0.49
FFAR1 O14842 1/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373212 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21235517 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21373214 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21373211 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21235418 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21373213 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21373209 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL20756762 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21235636 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1
SCHEMBL21373207 1.00 ALDH1A1 (0.61) ALDH1A1HPGDFAAHMAPTCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2512449-B1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS UNIV BRITISH COLUMBIA (CA) 2019-08-07 EP disclosed
US-20160317676-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-11-03 US disclosed
US-20160317676-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-11-03 US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 US disclosed
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-17 US disclosed
WO-2011075656-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130017223-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS LIPA, APOB, LIPC ALDH1A1 4338/4885HPGD 4248/4885FAAH 1523/4885
US-20160317676-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS LIPA, APOB, LIPC ALDH1A1 4338/4885HPGD 4248/4885FAAH 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.